Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer’s disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
Metrics to compare | NXL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNXLPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.2x | −3.9x | −0.5x | |
PEG Ratio | 0.11 | −0.25 | 0.00 | |
Price/Book | 8.0x | 2.9x | 2.6x | |
Price / LTM Sales | 142.2x | 3.3x | 3.2x | |
Upside (Analyst Target) | 371.9% | 38.8% | 42.0% | |
Fair Value Upside | Unlock | 8.1% | 6.6% | Unlock |